Alloy Therapeutics, a biotechnology ecosystem company and Wheeler Bio, a contract development and manufacturing organization (CDMO), will form a non-exclusive, preferred service offering to drive translation from discovery to CMC development and clinical material supply for ecosystem partners. The organizations are collaborating to provide a service experience for Alloy partners requiring CMC development services from Wheeler as a reliable CMC service provider for development and GMP manufacturing.
 
Alloy and Wheeler Bio are offering these services for existing and future ATX-Gx platform users and Alloy Discovery Service partners who also contract Portable CMC development services with Wheeler Bio.
 
Partners of both Alloy and Wheeler will receive the following services:
 
• Dollar-for-dollar reductions in Alloy commercial milestones matching Wheeler Portable CMC services contracted for ‘Lead-to-Tox’ and ‘Lead-to-Clinic’ programs.
• Free CMC consulting services to advise ecosystem partners on the translation from discovery to CMC development.
• Zero charge CHO pool generation for up to 4 leads, for Alloy partners contracting Wheeler’s Lead-to-Tox or Lead-to-Clinic Portable CMC programs.
• 50% reduction in initial payment for Alloy partners contracting Wheeler Lead-to-Clinic Portable CMC programs.
• Zero reservation fee required to hold manufacturing slots for Alloy partners contracting Wheeler full Lead-to-Clinic Portable CMC programs.
 
“Following every great antibody and bispecific discovery process, CMC becomes the critical path to treating patients. We developed this preferred offering with Wheeler to support Alloy’s partners with the highest quality cell line development and GMP manufacturing process possible,” said Errik Anderson, CEO and founder of Alloy Therapeutics. “Alloy is helping to lower the cost of drug development by reducing our partners’ downstream payments dollar-for-dollar on their path to the clinic.”
 
“By closely aligning Alloy’s discovery platform with Wheeler’s development and manufacturing platform, our ecosystem clients benefit immensely by skipping the CDMO RFP process while reducing risk in tech transfers,” said Jesse McCool, CEO, and co-founder of Wheeler Bio. “Our bioprocess models are in lockstep with ATX-Gx derived antibodies, so Wheeler services represent the best, most efficient use of CMC capital for Alloy partners.”